Day: August 24, 2021

Figure #1 – North Limb Project Drill Grids Plan MapFigure #1 – North Limb Project Drill Grids Plan MapFigure #2 – Armand Lake Volcanic Complex Drillhole Plan MapFigure #2 – Armand Lake Volcanic Complex Drillhole Plan MapFigure #3: Section A-150 (NL21-06)Figure #3: Section A-150 (NL21-06)Figure #4: Section A+725 (NL21-07, NL21-08)Figure #4: Section A+725 (NL21-07, NL21-08)Figure #5: Section A+475 (NL21-09)Figure #5: Section A+475 (NL21-09)TORONTO, Aug. 24, 2021 (GLOBE NEWSWIRE) — Hemlo Explorers Inc. (the “Company”) (TSXV: HMLO) is pleased to provide an update on its drill program at the North Limb project, located 15 km north of the Hemlo Mine near Manitouwadge, Ontario.   Highlights:Two drill grids have been instituted to cover the entire North...

In vitro and in vivo data demonstrate favorable safety and potency against multiple dengue virus serotypes supporting ongoing clinical development of AT-752Dengue is the fastest-spreading mosquito-borne viral disease with an estimated 400 million infections each year globallyBOSTON, Aug. 24, 2021 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced the publication of data demonstrating the in vitro and in vivo activity of AT-752 against dengue virus infection, in the journal, Antimicrobial Agents and Chemotherapy. The article titled, “Evaluation of AT-752, a double prodrug of a guanosine nucleotide analog with in vitro and in vivo activity against dengue and other flaviviruses,” can be accessed here. The published data demonstrate that AT-752 has...

Company Plans to Submit an IND to Support a Phase 2 Clinical Trial of TNX-102 SL for the Treatment of Long COVID Long COVID Symptoms of Pain, Sleep Disturbance, Fatigue and Brain Fog Overlap with Symptoms of Fibromyalgia, for which TNX-102 SL is in Mid-Phase 3 Development Long COVID Afflicts More Than 30% of Patients Following Infection with SARS-CoV-2, the Virus that Causes COVID-19, and is Expected to be a Global Health Burden CHATHAM, N.J., Aug. 24, 2021 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it received the official minutes from a Type B pre-Investigational New Drug Application (IND) meeting with the U.S. Food and Drug Administration (FDA) to develop TNX-102 SL1 (cyclobenzaprine HCl sublingual tablets) as...

WINNIPEG, Manitoba, Aug. 24, 2021 (GLOBE NEWSWIRE) — DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: DLTNF) (“Delta 9” or the “Company”), is pleased to announce the grand opening of its thirteenth Delta 9 Cannabis retail store, and tenth cannabis store in the Province of Manitoba. Delta 9’s newest retail store is located in the City of Selkirk and is scheduled to open on August 26, 2021. “I am very proud of the fact that in spite of the pandemic our team has worked hard to continue our pace of growth,” said John Arbuthnot, CEO of Delta 9. “The Delta 9 brand is becoming more familiar in Western Canada and this new store location strengthens our network of stores and enables us to continue to offer the best selection of cannabis products; at the lowest prices, from the most popular cannabis manufacturers in Canada.” Established in 1882,...

SAN CLEMENTE, CA, Aug. 24, 2021 (GLOBE NEWSWIRE) — via NewMediaWire – Global WholeHealth Partners Corp. (OTC: GWHP) is readying for sales due to the transition from Emergency Use Status to Full FDA Approval of Vaccine developed by Pfizer-BioNTech, as stated in 8K filing 06/15/21.   The agreement between Global WholeHealth Partners Corp and Nunzia Pharmaceutical Inc. has been a great benefit to Global by Nunzia allowing Global to broker and sell through Nunzia’s agreement the vaccines, as stated in 8K filings 03/08/21, 06/09/21, 06/15/21, and 06/24/21.  Global WholeHealth Partners Corp. (OTC: GWHP), a multinational supplier of over 70+ FDA Approved Diagnostic Tests announces full FDA Approval of the First COVID-19 Vaccine distributed by the company. The U.S. Food and Drug Administration approved the first COVID-19 vaccine....

AGOURA HILLS, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and COVID-19, reported today that PulmoHealTM/ ArtiVedaTM has proven active against mild and moderate COVID-19 following the preplanned prospective analysis of ARTI-19 clinical trial (NCT05004753- A Prospective, Randomized, Multi-center, Open label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg capsule in Treatment of Adult Subjects with COVID-19). The study report will serve as the basis for Oncotelic’s regulatory submission for marketing approval of PulmoHealTM/ ArtiVedaTM. “The positive outcome of this well conducted clinical trial has validated our TGF-β platform against COVID-19....

A Media Snippet accompanying this announcement is available by clicking on the image or link above.A Media Snippet accompanying this announcement is available by clicking on the image or link above.A Media Snippet accompanying this announcement is available by clicking on the image or link above. VANCOUVER, British Columbia, Aug. 24, 2021 (GLOBE NEWSWIRE) — Extreme Vehicle Battery Technologies Corp. (the “Company” or “EV Battery Tech”) (CSE: ACDC) and its subsidiary IoniX Pro Battery Technologies Inc. (“IoniX Pro”) have completed manufacturing the first product in the series of the IoniX Pro Home SmartWallTM (the “SmartWall”). On January 6, 2021, the Company first announced the specifications of the SmartWall and now only 8 months later, the Company is very proud to announce that it has officially completed building, testing...

PORTLAND, Maine, Aug. 24, 2021 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that the FDA has issued a Technical Section Incomplete Letter covering the Chemistry, Manufacturing and Controls (CMC) Technical Section for Re-Tain® (Nisin A intramammary solution). The CMC Technical Section covers the commercial manufacturing requirements for the Drug Substance and resulting Drug Product. The Company previously received Technical Section Complete Letters from the FDA covering the other four major Technical Sections required for product approval. Re-Tain® is the Company’s new subclinical mastitis treatment...

Only industry conference focusing on all aspects of semiconductor wafer and die level probe testing MT. LAUREL, N.J., Aug. 24, 2021 (GLOBE NEWSWIRE) — inTEST Corporation (NYSE American: INTT), a global supplier of innovative test and process solutions for use in manufacturing and testing across a wide range of markets, including automotive, defense/aerospace, industrial, medical, semiconductor and telecommunications, announced today that its Electrical and Mechanical Solutions segment (EMS) will be a Gold-level sponsor of the 30th Anniversary SWTest 2021, the only industry conference that focuses on all aspects of semiconductor wafer and die level probe testing. The conference is scheduled to take place August 30-September 1, at the Rancho Bernardo Inn. inTEST EMS will be exhibiting at both the live and virtual events—Booth 201. “We...

This news release is not for distribution to United States newswire service or for dissemination in the United States Private Placement VANCOUVER, British Columbia, Aug. 24, 2021 (GLOBE NEWSWIRE) — Rugby Mining Limited (“Rugby” or the “Company”) (TSX-V: RUG) announces that its board of directors has approved a proposed private placement offering of up to 20,833,333 units (the “Units”) at a price of $0.12 per Unit for gross proceeds of up to $2,500,000 (the “Offering”). Completion of the Offering is one of the conditions of the recently announced proposed acquisition of Proximo Resources Pty Ltd (“Proximo”), see press release dated July 26, 2021 (the ”Transaction”). Each Unit will consist of one (1) common share and one (1) half common share purchase warrant (each whole common share purchase warrant a “Warrant”). Each Warrant will...